Study: Breakthrough designated drugs led to better clinical outcomes for patients with NSCLC

Drugs granted a breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) were more likely to yield better outcomes for patients with non-small cell lung cancer (NSCLC) compared with drugs that didn’t carry the designation, according to a recent analysis published in Clinical Cancer Research.